Aug 4 (Reuters) - New York City-based Pathos AI will pay $125 million upfront to a subsidiary of Alphamab Oncology for rights to an experimental drug for a type of breast cancer, the Chinese oncology ...

Eric Schadt, a serial entrepreneur and expert in computational biology, is leaving his post as Chief Scientist at Pathos AI ...

Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic Pathos assumes responsibility for early clinical development of ...

Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design. NEW YORK--(BUSINESS WIRE)--Pathos AI ...